Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS (AVATAR)

Capital Medical University

Status and phase: Unknown; Phase 4

Conditions: Acute Coronary Syndrome; Angioplasty

Treatments: Drug: additional rosuvastatin loading; Drug: placebo control

Study type: Interventional

Funder types: Other

Identifiers

NCT01245803

6998

Details and patient eligibility

About

Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

Enrollment: 400 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18-75 year old
• diagnosed as acute coronary syndrome
• Plan to PCI

Exclusion criteria

• STEMI patient
• emergency PCI(<2h) for NSTE-ACS
• History of liver disease and myopathy (ALT/AST>3 x upper limit of normal,CK>5 x upper limit of normal)
• TG>500mg/dl,CCr<30ml/min
• inflammatory disease
• allergic to rosuvastatin
• nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,et.al.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

400 participants in 2 patient groups, including a placebo group

rosuvastatin,one month,lipid lowering

Experimental group

Description:

additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI

Treatment:

Drug: additional rosuvastatin loading

sugar pill, one month

Placebo Comparator group

Description:

sugar pill is given 18-24hr and 4-6hr before PCI as control

Treatment:

Drug: placebo control